(Q41727048)

English

Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma

scientific article published on August 1990

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Malcolm Brenner

7

object named as

Brenner MK

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

5

object named as

Heslop HE

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

author name string

Gottlieb DJ

1

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Prentice HG

2

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Mehta AB

3

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Galazka AR

4

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Hoffbrand AV

6

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

language of work or name

0 references

publication date

1 August 1990

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

75

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

499-505

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1990.TB07789.X

21 January 2018

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1990.TB07789.X

21 January 2018

A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1990.TB07789.X

21 January 2018

Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1990.TB07789.X

21 January 2018

Identifiers

10.1111/J.1365-2141.1990.TB07789.X

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41727048&oldid=2060821394"